Selio System
Financiado
Development and commercialisation of a novel needle tract sealant system for pne...
Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsy
Every 30sec someone somewhere globally dies of lung cancer. EU records ~320,000 pa new lung cancer cases. Early lung cancer diagnosis can save lives through timely/efficient interventions. CT guided lung biopsy is the gold standar...
Every 30sec someone somewhere globally dies of lung cancer. EU records ~320,000 pa new lung cancer cases. Early lung cancer diagnosis can save lives through timely/efficient interventions. CT guided lung biopsy is the gold standard for lung cancer screening. However, it comes with 62% inherent risk of life-threatening complication pneumothorax (PTX)- a complete or partial lung collapse. PTX sufferers require further radiological scans, needle aspiration, chest tube insertion or surgery- requiring additional hospital stay & ~€15k cost-of-care. Currently no method or device prevents PTX during the percutaneous needle access of lung.
Our patented Selio System will be world’s first system specifically designed to prevent PTX occurring before biopsy even takes place. Used by an interventional radiologist before lung biopsy procedure in a 2 min ‘add-on’ to the current standard of care, Selio System pre-seals the needle tract in tissue, thereby preventing air & blood leak from those organs
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2022-09-28
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
SELIO MEDICAL LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
